• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Stem cells: Athersys, Pfizer start MultiStem clinical trial for inflammatory bowel disease

Stem cells: Athersys, Pfizer start MultiStem clinical trial for inflammatory bowel disease

March 15, 2011 By MedCity News

Athersys

Stem cell therapy developer Athersys (NSDQ:ATHX) and partner Pfizer (NYSE:PFE) have begun enrolling patients in a Phase II clinical trial for inflammatory bowel disease.

The trial marks an “important milestone” for Athersys because it’s the first time the company’s MultiStem treatment has advanced to a Phase II trial, CEO Gil Van Bokkelen said in a conference call with analysts to discuss the company’s quarterly financial numbers.

MultiStem is an off-the-shelf stem cell treatment derived from the bone marrow of adults or other nonembryonic sources. The cells have a drug-like effect that reduces inflammation, protects damaged tissue and forms new blood vessels. Athersys is pursuing several clinical applications for MultiStem, including heart attack, stroke, blood cancer and spinal injury.

MedCity News logo

Pfizer is bearing all the costs of the 126-patient inflammatory bowel disease study, Van Bokkelen said.

In addition to the clinical progress, another key benefit of working with Pfizer on the study is the opportunity for Athersys to forge future partnerships with the deep-pocketed pharmaceuticals giant, which posted $68 billion in revenue last year.

“That is certainly a possibility,” Van Bokkelen said when pressed by an analyst on future Pfizer collaborations. “I think Pfizer is excited by the work we’re doing together. I think the relationship is going extremely well.”

Athersys also announced plans to begin a Phase II trial of MultiStem for the treatment of acute myocardial infarction (heart attack) later this summer. The company is finalizing the study’s design and selecting a contract research organization to work with, Van Bokkelen said. Athersys is collaborating with Angiotech Pharmaceuticals on the heart attack application of MultiStem.

For a company with no products on the market like Athersys, clinical developments such as the Phase II trials always take precedence over earnings numbers. Nonetheless, the numbers did hold some positives for Athersys, primarily in the form of increased revenue thanks to the Pfizer collaboration and a similar deal with RTI Biologics to develop orthopedic implants.

Fourth-quarter revenue more than tripled to $3.3 million, while the company’s net loss for the quarter was $2.1 million, down from a $5 million loss in the year-ago quarter. More than $700,000 in federal grants from last year’s health reform legislation also provided a boost to revenue in the quarter.

For the full year, revenue quadrupled to $8.9 million, driven by the Pfizer and RTI deals. Athersys posted a net loss of $11.4 million compared with a loss of $15.4 million the prior year.

On. Dec 31, the company’s cash on hand stood at $15 million, though the number doesn’t take into account the proceeds of a $13 million stock sale in January. COO B.J. Lehmann declined to provide guidance on how long the cash would last Athersys when asked by an analyst.

Filed Under: News Well, Stem Cells Tagged With: Athersys Inc., Clinical Trials, Pfizer

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy